X0609 4 2026-05-15 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001337801 Scott Randal W. false C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 1 0 0 0 1 Common Stock 2026-05-15 4 M 0 10000 16.75 A 21589 D Common Stock 2026-05-15 4 S 0 6200 66.6878 D 15389 D Common Stock 2026-05-15 4 S 0 2088 67.5302 D 13301 D Common Stock 2026-05-15 4 S 0 1512 68.2303 D 11789 D Common Stock 2026-05-15 4 S 0 200 69.12 D 11589 D Common Stock 4000 I By Thinking Bench Capital LLC Stock Option (Right to Buy) 16.75 2026-05-15 4 M 0 10000 0 D 2033-06-21 Common Stock 10000 21501 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. /s/ Laura Woodhead, Attorney-in-Fact 2026-05-19